Edition:
United Kingdom

Stellar Biotechnologies Inc (SBOT.OQ)

SBOT.OQ on NASDAQ Stock Exchange Capital Market

2.19USD
23 May 2018
Change (% chg)

$0.08 (+3.79%)
Prev Close
$2.11
Open
$2.11
Day's High
$2.24
Day's Low
$2.05
Volume
17,690
Avg. Vol
9,977
52-wk High
$10.43
52-wk Low
$1.96

Chart for

About

Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-target... (more)
No analyst recommendations are available for .

Overall

Beta: 2.30
Market Cap(Mil.): $15.16
Shares Outstanding(Mil.): 10.52
Dividend: --
Yield (%): --

Financials

  SBOT.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.43 -- --
ROI: -32.77 1.57 14.38
ROE: -33.17 2.43 16.07

BRIEF-Stellar Acquisition Reduces Extension Date Of Initial Business Combination To August 24

* STELLAR ACQUISITION III INC. ANNOUNCES INCREASE IN MONTHLY CONTRIBUTION AMOUNT TO TRUST ACCOUNT POST-EXTENSION APPROVAL AND SHORTENING OF EXTENSION DATE TO AUGUST 24, 2018 Source text for Eikon: Further company coverage:

14 May 2018

BRIEF-Stellar Biotechnologies Announces Pricing Of $5.5 Mln Public Offering

* STELLAR BIOTECHNOLOGIES ANNOUNCES PRICING OF $5.5 MILLION PUBLIC OFFERING

11 May 2018

BRIEF-Stellar Biotechnologies Reports Q2 Loss Per Share Of $0.90

* STELLAR BIOTECHNOLOGIES REPORTS SECOND QUARTER FINANCIAL RESULTS

07 May 2018

BRIEF-Stellar Biotechnologies Announces One-For-Seven Reverse Split

* STELLAR BIOTECHNOLOGIES ANNOUNCES ONE-FOR-SEVEN REVERSE SPLIT

27 Apr 2018

BRIEF-Stellar Biotechnologies Reports Q1 Loss Per Share $0.13

* STELLAR BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

07 Feb 2018

BRIEF-Stellar Biotechnologies Appoints Pharma Licensing Expert To Board Of Directors

* STELLAR BIOTECHNOLOGIES APPOINTS PHARMA LICENSING EXPERT TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

25 Jan 2018

FACTBOX-Bitcoin may be king, but Ripple dark horse in crypto race

Jan 3 Bitcoin was the star of the white-knuckle ride cryptocurrencies offered in 2017 but lesser-known names, such as Ripple and Ethereum, are seen gaining prominence in 2018. While bitcoin jumped more than 1,200 percent last year, Ripple, created by the founder of bitcoin exchange Mt Gox, surged 35,000 percent in the same period. That means $100 invested in Ripple in January 2017 would have grown to about $35,000 at the start of this year. To be sure, bitcoin is stil

03 Jan 2018

Earnings vs. Estimates

No consensus analysis data available.